Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Capstone Holding Corp. stock logo
CAPS
Capstone
$5.00
-3.8%
$5.20
$4.90
$20.00
N/A125.290 shs300 shs
MLNTQ
Melinta Therapeutics
$0.11
$0.11
$0.06
$8.60
N/AN/AN/A32,900 shs
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
$5.20
$3.31
$0.52
$9.12
$2.04M0.549,053 shs3 shs
TRPX
Therapix Biosciences
$0.10
$0.23
$0.25
$4.69
$351KN/A1.59 million shs95,212 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Capstone Holding Corp. stock logo
CAPS
Capstone
0.00%0.00%0.00%0.00%-85.95%
MLNTQ
Melinta Therapeutics
0.00%0.00%0.00%0.00%0.00%
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
0.00%-5.45%+108.00%+133.18%+102.33%
TRPX
Therapix Biosciences
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Capstone Holding Corp. stock logo
CAPS
Capstone
N/AN/AN/AN/AN/AN/AN/AN/A
MLNTQ
Melinta Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
TRPX
Therapix Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Capstone Holding Corp. stock logo
CAPS
Capstone
N/AN/AN/AN/A
MLNTQ
Melinta Therapeutics
N/AN/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/AN/AN/AN/A
TRPX
Therapix Biosciences
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Capstone Holding Corp. stock logo
CAPS
Capstone
N/AN/AN/AN/AN/AN/A
MLNTQ
Melinta Therapeutics
N/AN/AN/AN/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/AN/AN/AN/AN/AN/A
TRPX
Therapix Biosciences
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Capstone Holding Corp. stock logo
CAPS
Capstone
N/AN/A0.00N/AN/AN/AN/AN/A
MLNTQ
Melinta Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
-$160KN/A0.00N/AN/AN/A-159.55%N/A
TRPX
Therapix Biosciences
-$4.79MN/A0.00N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Capstone Holding Corp. stock logo
CAPS
Capstone
N/AN/AN/AN/AN/A
MLNTQ
Melinta Therapeutics
N/AN/AN/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/AN/AN/AN/AN/A
TRPX
Therapix Biosciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Capstone Holding Corp. stock logo
CAPS
Capstone
N/AN/AN/A
MLNTQ
Melinta Therapeutics
N/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/A
0.15
0.15
TRPX
Therapix Biosciences
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Capstone Holding Corp. stock logo
CAPS
Capstone
2.55%
MLNTQ
Melinta Therapeutics
N/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/A
TRPX
Therapix Biosciences
14.32%

Insider Ownership

CompanyInsider Ownership
Capstone Holding Corp. stock logo
CAPS
Capstone
42.80%
MLNTQ
Melinta Therapeutics
60.30%
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
18.40%
TRPX
Therapix Biosciences
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Capstone Holding Corp. stock logo
CAPS
Capstone
46N/AN/ANot Optionable
MLNTQ
Melinta Therapeutics
290N/AN/ANot Optionable
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
1392,000320,000Not Optionable
TRPX
Therapix Biosciences
93.51 millionN/ANot Optionable

TRPX, CAPS, PKPH, and MLNTQ Headlines

SourceHeadline
Anixa Biosciences Stock (NASDAQ:ANIX), Analyst Ratings, Price Targets, PredictionsAnixa Biosciences Stock (NASDAQ:ANIX), Analyst Ratings, Price Targets, Predictions
benzinga.com - December 12 at 5:48 AM
Sagimet Biosciences Inc (SGMT)Sagimet Biosciences Inc (SGMT)
investing.com - August 23 at 7:29 AM
PBIO Pressure BioSciences, Inc.PBIO Pressure BioSciences, Inc.
seekingalpha.com - August 1 at 3:24 PM
Cannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017s IPOsCannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOs
thestreet.com - January 19 at 7:59 PM

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Capstone logo

Capstone

OTCMKTS:CAPS
Capstone Holding Corp., through its subsidiaries, engages in the distribution of masonry stone products in the United States. Its masonry stone products include manufactured and natural stone cladding products, natural stone landscape products and related goods for residential and commercial construction. The company was formerly known as Capstone Therapeutics Corp. and changed its name to Capstone Holding Corp. in February 2022. Capstone Holding Corp. was incorporated in 1987 and is headquartered in Tempe, Arizona. Capstone Holding Corp. operates as a subsidiary of BP Peptides, LLC.

Melinta Therapeutics

OTCMKTS:MLNTQ
Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is based in Morristown, New Jersey. On December 27, 2019, Melinta Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Peak Pharmaceuticals logo

Peak Pharmaceuticals

OTCMKTS:PKPH
Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ.

Therapix Biosciences

NASDAQ:TRPX